Last updated on April 2019

The Paediatric EVICEL Soft Tissue and Parenchymal Organ Bleeding Study


Brief description of study

To evaluate the safety and effectiveness of EVICEL Fibrin Sealant (Human) as an adjunct to achieve haemostasis during surgery in paediatric patients.

Detailed Study Description

This is a prospective, randomized, controlled, clinical study comparing EVICEL to SURGICEL, as an adjunct to haemostasis when conventional methods of controlling bleeding are ineffective or impractical during surgery in paediatric patients.

At least 40 qualified paediatric subjects with an appropriate mild or moderate Target Bleeding Site (TBS) will be randomized in a 1:1 allocation ratio to either EVICEL or SURGICEL. Haemostasis will be assessed at 4, 7 and 10 minutes from randomization.

Enrolment will be staggered by age (as required by the European Medicines Agency (EMA) Paediatric Committee). The first group enrolled will include at least 36 subjects aged 1 years to <18 years of age. When enrolment of the first group is complete; enrolment of a subsequent group will commence and include at least 4 subjects from birth (including neonates 37 weeks gestation) to <1 years of age.

Subjects will be followed post-operatively through hospital discharge and at 30 days (14 days) post-surgery.

Clinical Study Identifier: NCT02227706

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.